Characterization of cannabis use by patients with myotonic dystrophy type 1: A pilot study

Beauchesne, William; Savard, Catherine; Côté-Hamel, Marika; Poliquin, Émilie; Gagné-Ouellet, Valérie; Gagnon, Cynthia; Tremblay, Karine

doi:10.1016/j.nmd.2021.01.003

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Myotonic Dystrophies

Silvestri,

Modoni

2023

Current Clinical Neurology

View full text Add to dashboard Cite

Myotonic Dystrophies

Silvestri,

Modoni

2023

Current Clinical Neurology

View full text Add to dashboard Cite

Current Treatment Options for Patients with Myotonic Dystrophy Type 2

Montagnese

2021

Curr Treat Options Neurol

View full text Add to dashboard Cite

Purpose of the review Myotonic dystrophy types 1 and 2 are frequent forms of muscular dystrophies in adulthood. Their clinical differences need to be taken into account for the most appropriate treatment of patients. The aim of this article is to provide an overview on the current and upcoming therapeutic options for patients with myotonic dystrophy type 2 (DM2). Recent findings At the moment, no disease-modifying therapies are available for DM2; next-generation therapies may however be available in the near future. In the meanwhile, the symptomatic management of patients has greatly improved, thank to the production of consensus-based standards of care and the growing evidence of efficacy of anti-myotonic drugs, promising employment of cannabinoids for symptom’s relief, regular monitoring, and early detection of treatable extra-muscular manifestations. Summary The treatment of DM2 is currently symptomatic and relies on the coordinated intervention of a multidisciplinary team. It remains to be determined whether upcoming causal therapies for myotonic dystrophy type 1 will be applicable also in DM2.

show abstract

Myotone Dystrophien, nichtdystrophe Myotonien und periodische Paralysen

Schneider-Gold,

Weber

2024

DGNeurologie

View full text Add to dashboard Cite

Characterization of cannabis use by patients with myotonic dystrophy type 1: A pilot study

Cited by 5 publications

References 23 publications

Myotonic Dystrophies

Myotonic Dystrophies

Current Treatment Options for Patients with Myotonic Dystrophy Type 2

Myotone Dystrophien, nichtdystrophe Myotonien und periodische Paralysen

Contact Info

Product

Resources

About